Wedbush Has Pessimistic Outlook of KNSA FY2024 Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Research analysts at Wedbush decreased their FY2024 EPS estimates for shares of Kiniksa Pharmaceuticals in a research note issued on Tuesday, October 29th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.42) for the year, down from their previous forecast of ($0.16). Wedbush currently has a "Outperform" rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.29) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.09 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.49 EPS, FY2026 earnings at $1.08 EPS and FY2027 earnings at $1.47 EPS.

Other equities analysts have also recently issued reports about the company. Evercore ISI increased their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a "buy" rating and a $40.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $34.60.

Kiniksa Pharmaceuticals Trading Down 1.8 %

Shares of KNSA traded down $0.42 during trading hours on Thursday, reaching $22.59. The stock had a trading volume of 412,709 shares, compared to its average volume of 412,801. Kiniksa Pharmaceuticals has a 12 month low of $14.12 and a 12 month high of $28.15. The firm has a 50-day simple moving average of $25.57 and a 200 day simple moving average of $22.42. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -140.81 and a beta of 0.33.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. During the same quarter in the prior year, the business earned ($0.20) earnings per share. Kiniksa Pharmaceuticals's revenue for the quarter was up 67.4% on a year-over-year basis.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the firm's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the sale, the chief operating officer now owns 119,911 shares in the company, valued at $3,226,805.01. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,692 shares of company stock worth $2,950,315. Corporate insiders own 54.57% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. AlphaCentric Advisors LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $287,000. Harbor Capital Advisors Inc. bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $2,438,000. Rice Hall James & Associates LLC raised its stake in shares of Kiniksa Pharmaceuticals by 8.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company's stock worth $16,234,000 after purchasing an additional 49,000 shares during the period. AMI Asset Management Corp bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $1,281,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Kiniksa Pharmaceuticals by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company's stock worth $195,000 after purchasing an additional 3,076 shares during the period. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.